Isotechnika Inc. appoints two new senior company officers

    EDMONTON, Oct. 10 /CNW/ - Isotechnika Inc. is pleased to announce that
effective October 10, 2007, Mr. Clemens Kaiser will assume the role of
Executive Vice President and Chief Marketing Officer. This position has been
created to focus on pre-commercialization and commercialization efforts for
the Company's lead drug, ISA247.
    Mr. Kaiser comes with extensive experience in the pharmaceutical industry
as he has held numerous executive positions within the Bayer organization.
After joining the Bayer Healthcare Division in 1984, he held positions with
increasing operational responsibilities in the Philippines, South Africa,
Canada, and Greater China. Between 1994 and 1998, Mr. Kaiser was a Member of
the Bayer Pharmaceutical Executive Management Committee and also responsible
for Bayer's Pharmaceutical Business in Asia, Australia, Latin America, Middle
East, Africa and Eastern Europe. During this time, many important milestones
were reached and he became, among other achievements, the first Chairman of
Bayer Healthcare China. Most recently, Mr. Kaiser was President and CEO of
Exatec LLC, a General Electric technology joint venture. Mr. Kaiser received a
degree in Business and Economics from the Free University in Berlin.
    As Chief Marketing Officer, Mr. Kaiser will oversee global marketing,
licensing and business development operations of Isotechnika. Mr. Kaiser will
also be responsible for identifying, conducting and concluding licensing and
partnership discussions and negotiations for current and future Isotechnika
compounds for all markets. Furthermore, he will be responsible for developing
target product profiles and providing input into clinical programs to optimize
the Company's products in global markets. As a member of the Senior Management
Executive group, he will also provide guidance and input for Isotechnika's
Investor Relations. "With uveitis and psoriasis already in Phase 3 and
transplant about to move into Phase 3, Isotechnika will increase its
activities with all partners to ensure expeditious regulatory approval and
launch of ISA247. I am excited to join Isotechnika at this stage and
compliment the team that has done a terrific job so far," states Mr. Kaiser.
"It is imperative that the Companies' resources are now focused on finding the
shortest way to market so that ISA247 is available to patients around the
world as soon as possible. Preparing for global product launch in three
different indications requires all the team's attention".
    The Company is also pleased to announce the appointment of Dr. Derrick
Freitag to the Senior Management Executive group as Chief Scientific Officer,
effective October 10, 2007. Dr. Freitag's new role ensures that scientific
resources are deployed to optimally support our drug development programs.
    Dr. Freitag has worked with Isotechnika since 1996 and recently held the
position of Senior Director, Biopharmaceutics. In 1994, Dr. Freitag received
his Ph.D. in Pharmaceutical Sciences specializing in drug metabolism from the
University of Alberta. Since joining Isotechnika, Dr. Freitag has held
numerous positions with increasing responsibilities in the Company's drug
metabolism program, the analytical chemistry laboratory, and the toxicology
and drug development programs. Since 2005, Dr. Freitag has been an Adjunct
Professor with the Faculty of Pharmacy and Pharmaceutical Sciences at the
University of Alberta in Edmonton. He has numerous scientifically reviewed
journal articles and abstracts. "My goal is to ensure that our Company's basic
science is translated into optimal patient therapy. By applying basic science
to patient outcomes, we can ensure patient care is at its best by achieving
that fine balance between optimal efficacy and minimal side effects," states
Dr. Freitag.
    "My job is to make sure that we are fully prepared to enter the
marketplace with ISA247 and that we have the scientific basis and recognition
to support the market introduction," stated Dr. Robert Foster, Isotechnika's
Chairman & Interim CEO. "From over 10 years of intensive research and
development, we have generated volumes of data to support our confidence in
this important immunosuppressive drug. ISA247 with its significantly improved
safety profile should put us in good stead relative to other therapies in the
transplant, psoriasis and uveitis marketplaces. Patients, clinicians and
investors should all benefit from our strategy."

    About Isotechnika
    Edmonton-based Isotechnika Inc. is an international biopharmaceutical
company focused on the discovery and development of novel immunosuppressive
therapeutics that are designed to offer advantages over other currently
available treatments while offering therapeutic choices to clinicians.
Isotechnika looks to become the market leader of drug therapies for
indications such as transplantation of solid organs (with Hoffman La Roche)
and treatment of autoimmune disorders such as uveitis (with Lux Biosciences)
and psoriasis.
    Calcineurin inhibitors are used in the vast majority of all transplant
patients from the time of transplant, continuing for the entire life of the
patient. The market for these drugs currently exceeds $2 billion annually. Use
of the only other two marketed calcineurin inhibitors, cyclosporin and
tacrolimus, while both efficacious, is associated with various significant
safety drawbacks.
    Isotechnika's lead drug, ISA247, has successfully completed a Phase 3
Canadian trial for the treatment of moderate to severe psoriasis. ISA247 is
currently being investigated in a Phase 3 European/Canadian psoriasis trial
and a Phase 2b North American trial for the prevention of kidney graft
rejection subsequent to transplantation. Our partner, Lux Biosciences, is
currently conducting three separate Phase 2/Phase 3 trials investigating
ISA247 as a treatment for uveitis.
    Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol "ISA". More information on Isotechnika can be found

    Partnerships with Isotechnika Inc.
    -   Hoffman La Roche (April 9, 2002) licensed the worldwide rights to
        develop and commercialize ISA247 for all transplant indications.

    -   Atrium Medical Corporation (September 30, 2005) exclusive worldwide
        licensing agreement for use of ISA247 and TAFA93 with drug eluting
        devices for non-systemic treatment of vascular, cardiovascular,
        target vessel and tissue disorders.

    -   Cellgate Inc. signed an option agreement (April 25, 2006), granting
        an option to obtain an exclusive license to develop and commercialize
        patented transporter technology for topical delivery of ISA247 in
        patients suffering from mild to moderate psoriasis.

    -   Lux Biosciences Inc. of Jersey City, New Jersey (May 25, 2006),
        Jersey City, New Jersey granted worldwide rights to develop and
        commercialize ISA247 for the treatment and prophylaxis of all
        ophthalmic diseases.

    Forward-Looking Statements
    This press release may contain forward-looking statements. Forward
looking statements, including the Company's belief as to the potential of its
products, the Company's expectations regarding the issuance of additional
patents and the Company's ability to protect its intellectual property,
involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the forward
looking statements. Such risks and uncertainties include, among others, the
availability of funds and resources to pursue research and development
projects, the ability to economically manufacture its products, the potential
of its products, the success and timely completion of clinical studies and
trials, the Company's ability to successfully commercialize its products, the
ability of the Company to defend its patents from infringement by third
parties, and the risk that the Company's patents may be subsequently shown to
be invalid or infringe the patents of others. Investors should consult the
Company's quarterly and annual filings with the Canadian commissions for
additional information on risks and uncertainties relating to the
forward-looking statements. Investors are cautioned against placing undue
reliance on forward-looking statements.

    %SEDAR: 00010508E

For further information:

For further information: Dr. Robert Foster, Chairman & Interim CEO,
Isotechnika Inc., Phone: (780) 487-1600 (x222), Fax: (780) 484-4105, E-mail:; Stephanie Gillis-Paulgaard, Director, Corporate
Communications, Isotechnika Inc., Phone: (780) 487-1600 (x243), Fax: (780)
484-4105, E-mail:

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890